When evaluating the Dihexa peptide price for analytical and in vitro studies, researchers must look beyond base cost to assess structural verification, purity guarantees, and lot-to-lot consistency. In preclinical neurobiology, Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) serves as a high-affinity HGF/c-Met receptor pathway agonist investigated for synaptogenesis and neuronal plasticity.
When evaluating the Dihexa peptide price for analytical and in vitro studies, researchers must look beyond base cost to assess structural verification, purity guarantees, and lot-to-lot consistency. In preclinical neurobiology, Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) serves as a high-affinity HGF/c-Met receptor pathway agonist investigated for synaptogenesis and neuronal plasticity.
The dihexa peptide price typically ranges based on synthesized milligram quantity, structural purity levels, and rigorous analytical validation. Raw research-grade Dihexa usually costs between $40 to $120 per vial depending on mass (5mg vs 10mg) and verification depth, where premium pricing reflects ISO 17025 third-party testing, RP-HPLC purity exceeding 99%, and verified endotoxin thresholds.
In institutional settings, procurement decisions are guided by total cost of quality rather than low sticker price. Inadequate purification or unverified lyophilization can introduce residual trifluoroacetate (TFA) salts, synthesis side-products, or bacterial endotoxins that invalidate cell culture data. Investing in fully characterized Dihexa 10mg research vials ensures that experimental models yield reproducible, publication-grade results without confounding variables.
Furthermore, pricing scales significantly when transitioning from benchtop exploratory vials to bulk institutional procurement. Principal investigators ordering through wholesale laboratory accounts benefit from tiered volume discounts, customized batch sizes, and reserved single-lot production runs tailored to longitudinal research programs.
Dihexa is an oligopeptide derivative synthesized from Angiotensin IV, designed specifically to maintain metabolic stability while exhibiting potent binding affinity for hepatocyte growth factor (HGF). Its formal chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Unlike native Angiotensin IV, which undergoes rapid enzymatic degradation by aminopeptidases, Dihexa features terminal modifications that extend its half-life in physiological buffer solutions.
The primary biochemical target of Dihexa is the HGF/c-Met signaling complex. In vitro binding assays demonstrate that Dihexa binds to HGF with high affinity (Kd in the low picomolar range), facilitating the dimerization of HGF and subsequent transphosphorylation of the c-Met receptor tyrosine kinase. Activation of the c-Met receptor triggers downstream intracellular cascades, including the Ras/Ref/MEK/ERK and PI3K/Akt pathways.
Preclinical data indicate that signaling through the c-Met receptor is crucial for dendritic arborization, spinogenesis, and the upregulation of key synaptic proteins such as synaptophysin and PSD-95. Researchers studying neurodegenerative models, traumatic brain injury (TBI) assays, and synaptogenesis utilize Dihexa to map structural remodeling mechanisms in primary neuronal cultures.
Academic literature surrounding Dihexa centers on its capacity to promote spinogenesis—the formation of new dendritic spines—at sub-nanomolar concentrations. In primary hippocampal neuron cultures, application of Dihexa at concentrations as low as 10^-12 M demonstrated significant increases in dendritic spine density within 5 to 7 days of administration, outperforming native neurotrophic factors like BDNF in specific in vitro paradigms.
In animal models of cognitive impairment, rodent studies evaluated Dihexa's effect on spatial learning and memory retrieval using the Morris Water Maze. Rodents displaying scopolamine-induced or transgenic cognitive deficits exhibited marked restoration of spatial memory tasks following systemic or central administration of the compound, correlated with elevated synaptic density in CA1 hippocampal regions.
Further exploratory research examines Dihexa's role in hepatocyte signaling and peripheral tissue regeneration. Because c-Met activation is involved in cell survival, proliferation, and cell motility across multiple tissue types, investigators in tissue engineering rely on our broader catalog of research peptides to compare HGF agonists against other regenerative signaling molecules.
The absolute dihexa peptide price is driven primarily by the complexity of its chemical synthesis and the purification steps required to achieve research-grade standards. Dihexa synthesis relies on Solid-Phase Peptide Synthesis (SPPS) or liquid-phase fragment condensation, followed by multi-stage purification protocols. Each step in purification directly impacts final yield and total manufacturing cost.
Standard synthesis generates crude peptide containing truncated sequences, unreacted reagents, and organic solvents. To reach purity levels >99%, manufacturers must perform repeated Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) runs using specialized C18 column matrices. High-purity yields require greater solvent consumption, specialized chromatographic media, and extended instrument run times, which are reflected in the unit price.
Lyophilization (freeze-drying) under sterile conditions represents another crucial cost factor. Proper lyophilization removes residual organic solvents while preserving peptide secondary structure and creating a stable, easily soluble cake. Inferior drying techniques leave moisture or solvent residues that compromise shelf life and alter dry weight calculations during lab preparation.
To protect experimental integrity, laboratory buyers must demand complete analytical documentation for every lot of Dihexa. A reliable supplier provides a batch-specific Certificate of Analysis (COA) containing double analytical confirmation: RP-HPLC for chemical purity and Electrospray Ionization Mass Spectrometry (ESI-MS) for identity and molecular weight verification.
RP-HPLC chromatograms should show a single sharp peak representing the target molecule, with total area integration indicating a purity of 99% or higher. ESI-MS spectrum analysis confirms that the observed molecular mass matches the theoretical mass of N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide (MW 504.66 g/mol), ruling out sequence mismatches or incomplete synthesis fragments.
In addition to purity and identity, endotoxin testing is mandatory for cell culture and preclinical animal models. Bacterial endotoxins (lipopolysaccharides) induce inflammatory signaling in microglial and cell culture models, corrupting experimental data. Standard PX1 Research lots undergo Chromogenic LAL (Limulus Amebocyte Lysate) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg.
When designing neuroplasticity and cognitive research protocols, scientists frequently compare Dihexa against other established peptide compounds within the PX1 research library. Understanding differences in receptor pathways, operational concentrations, and pricing models allows laboratories to optimize their experimental designs and budget allocations.
For instance, Semax research protocols focus heavily on Melanocortin receptor interaction and the upregulation of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). While Dihexa targets the HGF/c-Met axis to drive rapid dendritic arborization, Semax acts via neurotrophin modulation and vascular signaling. Combining or comparing Semax 30mg powder with Dihexa provides researchers with complementary datasets on neurotrophic versus growth factor pathways.
Similarly, Selank preclinical studies examine enkephalinase inhibition, GABAergic modulation, and cytokine regulation, making it ideal for neuro-immunology assays rather than structural synaptogenesis. For extracellular matrix remodeling and cellular survival models, scientists often cross-reference Dihexa against BPC-157 analytical standards or GHK-Cu peptide assays to differentiate between localized tissue repair and central synaptic remodeling.
Dihexa possesses distinct physicochemical properties that dictate specific handling and reconstitution protocols in the laboratory. Due to the hydrophobic nature of its N-terminal hexanoyl group and isoleucine side chain, lyophilized Dihexa exhibits limited direct solubility in pure aqueous solutions like standard Phosphate-Buffered Saline (PBS) or sterile water at high concentrations.
To achieve complete solubilization for in vitro assays, researchers typically dissolve the lyophilized powder first in dimethysulfoxide (DMSO) or pure ethanol to create a concentrated master stock solution (e.g., 10 mM to 50 mM). Once fully dissolved in organic solvent, the master stock can be diluted into cell culture media or aqueous buffers to reach target working concentrations, keeping the final DMSO concentration below 0.1% v/v to avoid cellular toxicity.
Reconstitution should always take place under a laminar flow hood using sterile, pyrogen-free pipette tips and solvents. Gentle vortexing or mild sonication may be applied if necessary, but solutions should never be subject to high-shear mechanical agitation that could induce aggregation or peptide denaturation.
Maintaining the chemical integrity of Dihexa over extended experimental timelines requires adherence to strict temperature and environmental controls. Lyophilized Dihexa powder is highly stable when stored in a desiccated environment at -20°C or -80°C, protected from direct light exposure.
Under sub-zero desiccated storage, lyophilized Dihexa retains its structural purity and biological activity for up to 24 months. Avoid frequent opening of storage vials at room temperature before equilibration, as atmospheric moisture can condense onto the cold lyophilized cake, causing gradual hydrolysis of peptide bonds over time.
Once reconstituted into liquid stock solutions, Dihexa aliquots should be frozen immediately at -80°C in single-use volumes to eliminate repeated freeze-thaw cycles. Liquid aliquots stored at -80°C remain stable for up to 3 to 6 months, whereas working dilutions kept at 4°C should be utilized within 24 to 48 hours to prevent potential degradation or precipitate formation.
For universities, contract research organizations (CROs), and biotechnology firms, securing a reliable supply of high-purity Dihexa involves more than individual retail orders. Establishing formal supplier relationships ensures lot uniformity across multi-phase studies, reducing batch-to-batch variance that can introduce statistical noise into empirical datasets.
PX1 Research offers comprehensive support for institutional buyers, providing batch reservation services, customized vial fills (from 5mg up to gram-scale quantities), and tailored analytical packages. Our dedicated wholesale laboratory accounts allow procurement teams to access volume-tiered pricing structures and dedicated account management.
All institutional shipments are dispatched directly from our ISO-compliant facilities in California and Arizona. Utilizing specialized protective packaging and temperature-controlled logistics, PX1 guarantees that delicate research compounds arrive intact and fully stabilized, supported by same-day dispatch for orders placed Monday through Friday.
At PX1 Research, we recognize that valid scientific discoveries depend entirely on the precision and quality of your starting materials. Unlike re-sellers who rely on unverified overseas imports, PX1 oversees strict quality assurance controls rooted in American manufacturing and independent validation.
Every batch of Dihexa in our inventory undergoes independent ISO 17025 accredited laboratory testing. We publish lot-specific COAs featuring high-resolution RP-HPLC chromatograms, mass spectrometry reports, and quantified endotoxin limits. This transparent validation framework ensures that your lab receives exactly what is specified on the vial label—100% pure, unadulterated research compound.
Whether your team is investigating HGF/c-Met signaling mechanisms, mapping dendritic spine density, or publishing comparative neurobiology studies, PX1 Research provides the material certainty required for advanced laboratory science.
What determines the dihexa peptide price across different suppliers?
Dihexa peptide price variations are primarily driven by synthesis method quality, final chromatographic purity (e.g., >99% vs <95%), mass quantity per vial, and the depth of analytical verification provided (such as ISO 17025 COAs with HPLC, MS, and LAL endotoxin testing).
What is the primary target pathway for Dihexa in preclinical research?
Dihexa is a high-affinity small-molecule agonist of the Hepatocyte Growth Factor (HGF) system. It binds HGF to dimerize and activate the c-Met receptor tyrosine kinase pathway, which is studied for synaptogenesis, dendritic arborization, and cell survival.
Why is third-party LC-MS and RP-HPLC verification critical for Dihexa research batches?
RP-HPLC verifies chemical purity by measuring total area percentage of the target peak versus impurities, while ESI-MS confirms exact molecular weight (504.66 g/mol). Without these tests, researchers risk using contaminated or improperly synthesized sequence fragments that corrupt cell assays.
How should Dihexa be reconstituted for in vitro cell culture assays?
Because of its hydrophobic hexanoyl chain, Dihexa should first be dissolved in organic solvents such as DMSO or ethanol to create a concentrated stock solution. This stock can then be diluted into culture media or aqueous buffer, maintaining final DMSO levels below 0.1% v/v.
What are the standard endotoxin limits for PX1 Research Dihexa lots?
All PX1 Research Dihexa lots undergo Chromogenic LAL testing to ensure bacterial endotoxins remain below <0.01 EU/mg, preventing endotoxin-induced inflammatory responses in delicate cell culture or neuronal models.
Is Dihexa readily soluble in standard phosphate-buffered saline (PBS)?
No, Dihexa exhibits low direct aqueous solubility in plain PBS at high concentrations. Initial solubilization in DMSO or ethanol is recommended prior to aqueous buffer dilution.
How does Dihexa structurally differ from native Angiotensin IV?
Dihexa is an N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide derivative of Angiotensin IV modified at its N- and C-terminals to enhance enzymatic resistance and extend half-life in physiological media.
Can institutional research facilities establish wholesale accounts for bulk Dihexa orders?
Yes, PX1 Research provides wholesale laboratory accounts for university labs, CROs, and biotech firms, offering volume discounts, lot reservation, custom packaging, and direct institutional billing.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.